Entellus Medical, which sells a minimally invasive treatment to open obstructed sinus pathways, announced terms for its IPO on Thursday. The Plymouth, MN-based company plans to raise $70 million by offering 4.4 million shares at a price range of $15 to $17. At...read more
This week's 10 IPOs largely disappointed as 70% were forced to price below the proposed range and 80% closed the week up 1% or less. Before this week, only 36% of IPOs this year had first-day pops of 1% or less. The enthusiasm for last week's ...read more
Two of the four IPOs on Thursday broke issue after pricing below the range. Less than a quarter of IPOs in the past three months have traded down on the first day. The top performer, Intersect ENT (XENT), priced at the low end and gained 18%. The...read more
Intersect ENT, which sells absorbable nasal implants for post-surgical sinusitis relief, raised $55 million by offering 5.0 million shares at $11, the low end of the range of $11 to $13. Intersect ENT plans to list on the NASDAQ under the symbol XENT. Intersect...read more
Sinus balloons for sale: Entellus Medical sets terms for $70 million IPO
Entellus Medical, which sells a minimally invasive treatment to open obstructed sinus pathways, announced terms for its IPO on Thursday. The Plymouth, MN-based company plans to raise $70 million by offering 4.4 million shares at a price range of $15 to $17. At...read more
US IPO Pricing Recap: The crazy chicken flies while 8 IPOs trade down or flat
This week's 10 IPOs largely disappointed as 70% were forced to price below the proposed range and 80% closed the week up 1% or less. Before this week, only 36% of IPOs this year had first-day pops of 1% or less. The enthusiasm for last week's ...read more
Thursday saw four IPOs raise under $100 million; two broke issue
Two of the four IPOs on Thursday broke issue after pricing below the range. Less than a quarter of IPOs in the past three months have traded down on the first day. The top performer, Intersect ENT (XENT), priced at the low end and gained 18%. The...read more
Intersect ENT prices IPO at $11, the low end of the range
Intersect ENT, which sells absorbable nasal implants for post-surgical sinusitis relief, raised $55 million by offering 5.0 million shares at $11, the low end of the range of $11 to $13. Intersect ENT plans to list on the NASDAQ under the symbol XENT. Intersect...read more